Aripiprazole Tablet
Product Images NDC 68071-3906

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68071-3906). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3906 4)

Aripiprazole 10 mg tablets label from NuCare Pharmaceuticals, Inc. The label indicates a 14-count tablet package with rectangular, bevel edged biconvex light pink tablets debossed with '1' on one side and '96' on the other. Manufactured by Hetero Labs Limited, India, the label includes NDC 68071-3906 and cautions to keep out of reach of children, storing at controlled temperature 68-77°F.*

FDA Label Image

Aripiprazolefigure1 (Aripiprazolefigure1)

A pharmacokinetic chart showing the fold change and 90% confidence intervals of aripiprazole when coadministered with various drugs. It displays the impact on aripiprazole's AUC and Cmax relative to reference without interacting drug, for CYP3A4 inhibitors and inducers, CYP2D6 inhibitors, gastric acid blockers, and other substances like valproate, lithium, and lorazepam.*

FDA Label Image

Aripiprazolefigure2 (Aripiprazolefigure2)

A chart showing the effect of other drugs on the pharmacokinetics (AUC and Cmax) of Aripiprazole, specifically the dehydro-aripiprazole fold change with 90% confidence intervals. The x-axis represents change relative to reference without interacting drug, including CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and other drugs, illustrating their impact on Aripiprazole metabolism.*

FDA Label Image

Aripiprazolefigure3 (Aripiprazolefigure3)

A bar chart titled 'Effect of Aripiprazole on Other Drugs' showing fold change with 90% confidence intervals for various drugs including dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, 0-desmethylvenlafaxine, and escitalopram. The x-axis represents change relative to reference without interacting drug, ranging from 0.5 to 3.0, while the y-axis lists affected drugs and pharmacokinetic parameters (PK) measured like AUC, CMAX, and INR.*

FDA Label Image

Aripiprazolefigure4 (Aripiprazolefigure4)

A pharmacokinetic chart depicting Aripiprazole fold change with 90% confidence intervals in various special populations. The graph compares changes in AUC and Cmax relative to reference across factors such as CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment.*

FDA Label Image

Aripiprazolefigure5 (Aripiprazolefigure5)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' displaying fold change relative to reference on the x-axis and various factors on the y-axis, including CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and renal impairment severity, with data points showing AUC and Cmax values and their confidence intervals.*

FDA Label Image

Aripiprazolefigure6 (Aripiprazolefigure6)

Kaplan-Meier curve chart showing the proportion of subjects with relapse over days from randomization, comparing Aripiprazole and placebo groups. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion with relapse. The chart includes numbers of subjects at risk at various time points for both groups.*

FDA Label Image

Aripiprazolefigure7 (Aripiprazolefigure7)

A Kaplan-Meier curve chart showing the proportion of subjects with relapse over 182 days from randomization, comparing Aripiprazole and Placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The chart includes the number of subjects at risk at various time points for both groups.*

FDA Label Image

Aripiprazolefigure8 (Aripiprazolefigure8)

A Kaplan-Meier survival curve chart showing the proportion of subjects with relapse over 364 days from randomization, comparing Aripiprazole (solid line) to placebo (dashed line). The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Numbers of subjects at risk at various time points are listed below the x-axis for both groups.*

FDA Label Image

Aripiprazolefigure9 (Aripiprazolefigure9)

A line graph illustrating the change in YGTSS Total Tic Score from baseline over 8 weeks of treatment. The graph compares three groups: Abilify Low dose, Abilify High dose, and Placebo, showing tic score reduction trends across the treatment period.*

FDA Label Image

Aripiprazolestructure (Aripiprazolestructure)

Chemical structure diagram of the active ingredient Aripiprazole, showing its molecular framework including rings, nitrogen, oxygen, and chlorine atoms in the arrangement typical for this compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.